Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(14%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
29%
Ph phase_4
2
29%
Ph phase_2
2
29%
Ph early_phase_1
1
14%

Phase Distribution

1

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(3)

Detailed Status

unknown3
Completed2
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (14.3%)
Phase 22 (28.6%)
Phase 32 (28.6%)
Phase 42 (28.6%)

Trials by Status

active_not_recruiting114%
completed229%
withdrawn114%
unknown343%

Recent Activity

1 active trials
Showing 5 of 7
active_not_recruitingphase_3

TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

NCT05461339
completedphase_4

Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

NCT03709745
unknownearly_phase_1

Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents

NCT06205979
withdrawnphase_2

Combined Ranibizumab and Iluvien for Diabetic Macular Oedema

NCT03784443
unknownphase_3

Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation

NCT05138029
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05461339Phase 3

TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

Active Not Recruiting
NCT03709745Phase 4

Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

Completed
NCT06205979Early Phase 1

Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents

Unknown
NCT03784443Phase 2

Combined Ranibizumab and Iluvien for Diabetic Macular Oedema

Withdrawn
NCT05138029Phase 3

Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation

Unknown
NCT05386160Phase 4

Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy

Unknown
NCT03071055Phase 2

Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7